| __timestamp | Mesoblast Limited | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 54170000 | 2917513 |
| Thursday, January 1, 2015 | 65378000 | 7878291 |
| Friday, January 1, 2016 | 52263000 | 8366794 |
| Sunday, January 1, 2017 | 35072000 | 6610381 |
| Monday, January 1, 2018 | 27415000 | 6556000 |
| Tuesday, January 1, 2019 | 36983000 | 6930000 |
| Wednesday, January 1, 2020 | 50918000 | 8758000 |
| Friday, January 1, 2021 | 63586000 | 10806000 |
| Saturday, January 1, 2022 | 57967000 | 9844000 |
| Sunday, January 1, 2023 | 53107000 | 13481000 |
| Monday, January 1, 2024 | 23626000 |
Unleashing the power of data
In the competitive world of biotechnology, managing operational costs is crucial for survival and growth. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Soleno Therapeutics, Inc. and Mesoblast Limited from 2014 to 2023. Over this period, Mesoblast consistently reported higher SG&A expenses, peaking in 2015 with a 65% increase compared to Soleno's highest in 2023. However, Mesoblast's expenses showed a downward trend, decreasing by approximately 64% from 2015 to 2024. In contrast, Soleno's expenses grew steadily, culminating in a 362% increase by 2023. This divergence highlights differing strategic priorities: Mesoblast's focus on cost reduction versus Soleno's investment in growth. Missing data for Soleno in 2024 suggests a potential shift or restructuring. Understanding these trends offers valuable insights into each company's operational strategies and market positioning.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Soleno Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Soleno Therapeutics, Inc.
Summit Therapeutics Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Jazz Pharmaceuticals plc and Soleno Therapeutics, Inc.
Comparing SG&A Expenses: Lantheus Holdings, Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Cytokinetics, Incorporated and Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Opthea Limited and Mesoblast Limited
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and Mesoblast Limited
Cost Management Insights: SG&A Expenses for Viking Therapeutics, Inc. and Soleno Therapeutics, Inc.
CRISPR Therapeutics AG or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Merus N.V. vs Soleno Therapeutics, Inc.: SG&A Expense Trends